Announced details
Diagnosis and treatment of tick-borne infectious diseases, including SFTS, and diagnostic technologies and testing methods for emerging infectious diseases
A party to the agreement to establish the joint research chair. Since September 2025, the company has been in discussions with the research group of physician Nomura Toshihito (野村俊仁) of the Department of Infectious Diseases at Hiroshima University Hospital regarding joint research on the diagnosis and treatment of SFTS.
Headquarters: Higashihiroshima, Hiroshima Prefecture; President: Ochi Mitsuo (越智光夫). National university corporation.
Hiroshima University Hospital and the Graduate School of Biomedical and Health Sciences, Hiroshima University
The impact of this matter on results for the current fiscal year is minor.
The company does not address Contract Value / Offering price.
Japan Institute for Health Security website: “Trends in SFTS cases reported through the Infectious Disease Surveillance System” and “Occurrence of severe fever with thrombocytopenia syndrome (SFTS) in Japan and overseas”
| Item | Details |
|---|---|
| Names of Products / Services Covered | Rapid test kits using immunochromatographic assays to detect SFTS virus antigens, as well as diagnostic technologies and testing methods capable of addressing emerging infectious diseases in the future |
| Counterparty | National University Corporation Hiroshima University (Hiroshima University Hospital) |
| Counterparty overview | Headquarters: Higashihiroshima, Hiroshima Prefecture; President: Ochi Mitsuo (越智光夫). National university corporation. |
| Relationship with the Company | A party to the agreement to establish the joint research chair. Since September 2025, the company has been in discussions with the research group of physician Nomura Toshihito (野村俊仁) of the Department of Infectious Diseases at Hiroshima University Hospital regarding joint research on the diagnosis and treatment of SFTS. |
| Contract Date | Announced on 15 May 2026. The parties decided to enter into the agreement as of 1 June 2026. |
| Launch date | 1 June 2026 (scheduled; the date the joint research chair is established) |
| Applicable area | Diagnosis and treatment of tick-borne infectious diseases, including SFTS, and diagnostic technologies and testing methods for emerging infectious diseases |
| Location | Hiroshima University Hospital and the Graduate School of Biomedical and Health Sciences, Hiroshima University |
| Impact on Business Performance | The impact of this matter on results for the current fiscal year is minor. |
| Source | Japan Institute for Health Security website: “Trends in SFTS cases reported through the Infectious Disease Surveillance System” and “Occurrence of severe fever with thrombocytopenia syndrome (SFTS) in Japan and overseas” |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Against a backdrop of an increasing number of areas reporting SFTS and rising numbers of human and animal cases, the aim is to strengthen measures against tick-borne infectious diseases and infectious diseases in Japan by deepening industry-academia collaboration and advancing diagnostic and therapeutic research, academic and educational development, and practical applications in industry.